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Abstract
Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these
arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of
lung fibrosis by using different gene knock-out settings.
We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the
development of bleomycin-induced lung injury by comparing the responses in wild-type mice with
mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor
antagonist.
Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to
receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin
administration, BAL cell counts, lung histology with van Gieson for collagen staining and
immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed.
Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced
degree of lung damage and inflammation when compared to WT mice as shown by the reduction
of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase
activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung
injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining.
This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates
bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic
studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary
fibrosis, a disease that still represents a major challenge to medical treatment.
Published: 21 November 2006
Respiratory Research 2006, 7:137 doi:10.1186/1465-9921-7-137
Received: 12 July 2006
Accepted: 21 November 2006
This article is available from: http://respiratory-research.com/content/7/1/137
© 2006 Failla et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
Page 2 of 12
(page number not for citation purposes)
Background
Idiopathic pulmonary fibrosis (IPF) is the most common
interstitial pneumonias of unknown origin and one of the
most aggressive interstitial lung diseases. It is character-
ized by a chronic and progressive course leading to respi-
ratory failure with a median survival under 3 years [1-3].
The pathogenesis of this condition is not entirely under-
stood, but the activation and proliferation of fibroblasts
in response to multiple and microscopic episodes of alve-
olar epithelial injury is believed to be the main event
which ultimately leads to extracellular matrix compo-
nents remodelling, resulting in the irreversible distortion
of the lung architecture [4].
A number of studies suggest a causal role for leukotrienes
(LT) in lung fibrosis [5]. These are lipid mediators derived
by the hydrolysis from membrane phospholipids of ara-
chidonic acid by the phospholipase A2 and 5-lipoxygen-
ase[6]. Leukotriene B4 is elevated in the bronchoalveolar
lavage of patients with IPF [7,8]. Furthermore cys-LT and
LT-B4 are increased in lung homogenates of patients with
IPF, and the levels of these mediators were found to corre-
late with the extent of fibrosis in histological sections [9].
Increased LT levels have also been demonstrated in mice
lungs following intra-tracheal administration of bleomy-
cin [10].
The leukotrienes pathway has been recently dissected in
the bleomycin animal model of lung fibrosis using differ-
ent genetic backgrounds. Knocking out each of the
enzymes involved in the cascade from membrane phos-
pholipids to leukotrienes, such as phospholipase-A2, 5-
lipoxygenase (LO), as well as LTC4 synthase, invariably
attenuates fibrosis in mice [11-13]. However, results com-
ing from these genetically altered backgrounds have not
been confirmed using a pharmacological approach, so
that no data exist actually on the efficacy of selective drugs
targeted on the leukotrienes pathway approved today for
human use.
This lack of data prompted us to ascertain whether the
cysteinyl leukotrienes receptor-1 antagonist MK-571 and
the 5-LO specific inhibitor Zileuton were able to affect the
inflammatory and fibrosing process that characterize the
intratracheal instillation of bleomycin in mice.
Methods
Animals
Male CD mice (25–35 g; Harlan Nossan; Italy) were
housed in a controlled environment and provided with
standard rodent chow and water. Animal care was in com-
pliance with Italian regulations on protection of animals
used for experimental and other scientific purpose (D.M.
116192) as well as with the EEC regulations (O.J. of E.C.
L 358/1 12/18/1986).
Experimental groups
Mice were randomly allocated into the following groups:
(i) WT+BLEO group. Mice were subjected to bleomycin-
induced lung injury (N = 15), (ii) WT+saline group.
Sham-operated group in which saline was administered
instead of bleomycin, (N = 15). (iii) MK-571 group. Same
as the WT+BLEO group but mice were administered with
MK-571 delivered through a subcutaneous implanted
Alzet 2002 mini-osmotic pump (Durect Co., Cupertino,
CA, USA). This route of administration was preferred over
oral administration on the basis of unknown pharmacok-
inetic properties of MK571 because of constant drug deliv-
ery. The pump loaded with 200 μL of a 2.5 μg/μL MK-571
solution in PBS (Cayman Chemical, Ann Arbor, MI, USA)
had a release rate of 0.5 μL/hour during the 7 days of the
experimental setup, (N = 15). (iv) Sham+MK-571 group.
Identical to WT+saline group, except for the administra-
tion of MK-571 delivered as described above (N = 15). (v)
Zileuton group. Same as the WT+BLEO group but WT
mice were administered Zileuton by force-feeding
(Sequoia Research Products, Oxford, U.K.) with a 50 mg/
kg oral bolus 30 minutes after bleomycin instillation and
then daily in the subsequent days (N = 15). The concen-
tration of MK-571 was established on the basis of prelim-
inary experiments starting from what was available on
other animal models [14], while zileuton dose and route
administration was chosen according to our precedent
studies [15]. (vi) Sham+Zileuton. Identical to WT+saline
group, except for the administration of zileuton as previ-
ously described (N = 15).
Induction of lung injury by bleomycin
Mice received a single intratracheal instillation of saline
(0.9%) or saline containing bleomycin sulphate (1 mg/kg
body weight) in a volume of 50 μl and were killed after 7
days by pentobarbitone overdose.
Measurement of fluid content in lung
The wet lung weight was measured after careful excision of
extraneous tissues. The lung was exposed for 48 h at
180°C and the dry weight was measured. Water content
was calculated by subtracting dry weight from wet weight.
Histological examination
Excised lung were taken 7 days after injection of bleomy-
cin, processed as previously described[16], and stained by
the van Gieson stain for collagen. The severity of fibrosis
was semi-quantitatively assessed according to Ashcroft
and co-workers[17]. Briefly, the grade of lung fibrosis was
scored on a scale from 0 to 8 by examining randomly cho-
sen fields of the left middle lobe at a magnification of
×100. Criteria for grading lung fibrosis were as follows:
grade 0, normal lung; grade 1, minimal fibrous thickening
of alveolar or bronchiolar walls; grade 3, moderate thick-Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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ening of walls without obvious damage to lung architec-
ture; grade 5, increased fibrosis with definite damage to
lung structure and formation of fibrous bands or small
fibrous masses; grade 7, severe distortion of structure and
large fibrous areas; grade 8, total fibrous obliteration of
fields. Grades 2, 4 and 6 were used as intermediate pic-
tures between the aforementioned criteria. All sections
were scored by a single investigator in a blinded fashion.
Immunohistochemical localization of IL-1β and TNF-α
IL-1β and TNF-α were determined by immunohistochem-
istry as previously described [16]. Sections were incubated
overnight with anti-IL-1β or anti-TNF-α (Santa Cruz Bio-
technology Inc., Santa Cruz, CA, USA) polyclonal anti-
body (both at 1:500 in PBS, v/v). Specific labelling was
detected with a biotin-conjugated goat anti-rabbit IgG and
avidin-biotin peroxidase complex (DBA, Milan, Italy).
Controls included buffer alone or non-specific, purified
rabbit IgG. Immunocytochemistry photographs were
assessed by densitometry. By using Optilab Graftek soft-
ware on a Macintosh personal computer, the assay was
performed.
Myeloperoxidase activity assay
Myeloperoxidase (MPO) activity, an indicator of poly-
morphonuclear leukocyte (PMN) accumulation, was
determined as previously described in lung homogenates.
The rate of change in absorbance was measured spectro-
photometrically at 650 nm. MPO activity was defined as
the quantity of enzyme degrading 1 μMol of peroxide/
min at 37°C and was expressed in milli-units per g of wet
tissue.
Bronchoalveolar Lavage (BAL)
Seven days after bleomycin or saline solution instillation,
mice were euthanized and the trachea was cannulated.
Lungs were lavaged once with 0.5 ml D-PBS (GIBCO,
Paisley, U.K.). In >95% of the mice, the recovery volume
was over 0.4 ml. Total BAL cells were enumerated by
counting on a haemocytometer in the presence of trypan
blue. Cytospins were prepared from resuspended BAL
cells. A total of 400 cells were counted from randomly
chosen high power microscope fields for each sample.
Materials
Unless otherwise stated, all compounds were obtained
from Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.).
All other chemicals were of the highest commercial grade
available. All stock solutions were prepared in non-pyro-
genic saline (0.9% NaCl; Baxter, Italy, UK).
Statistical evaluation
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of N observations. For
the in vivo studies N represents the total number of ani-
mals studied, dead animals were replaced in further exper-
iments to reach the specified number of observations. In
the experiments involving histology or immunohisto-
chemistry, the figures shown are representative of at least
three experiments performed on different experimental
days. The results were analyzed by one-way ANOVA fol-
lowed by a Bonferroni post-hoc test for multiple compar-
isons. A P-value of less than 0.05 was considered
significant. Statistical analysis for survival data was calcu-
lated by Fisher's exact probability test. For such analyses,
p < 0.05 was considered significant.
Results
Histological examination of lung sections revealed signif-
icant tissue damage. Thus, when compared to lung sec-
tions taken from saline-treated animals, histological
examination of WT mice treated with bleomycin were
characterized by extensive inflammatory infiltration by
neutrophils, lymphocyte and plasma cells extending
through the lung epithelium, fibrosis and granulomas
were seen in perivascular region (Fig. 1a and 1b). The
inhibition of the leukotrienes activity in mice (animals
treated with either MK 571 or Zileuton) significantly pre-
vented lung inflammation induced by bleomycin admin-
istration (Figs. 1c and 1d, respectively).
Lung fibrosis grading [17] revealed a moderate to severe
fibrosis reaction after one week of bleomycin administra-
tion, which was significantly reduced in animals treated
with MK-571 and Zileuton (6.1+/-0.5 vs. 2.1+/-0.3 and
1.7+/-0.6, p < 0.01, Fig. 1e). Sham treated animals were
found to be constantly free from lung inflammation and
fibrosis.
Bleomycin elicited an inflammatory response character-
ized by the accumulation of water in lung as an indicator
of lung edema, (Fig. 1f) and neutrophils infiltration in the
lung tissues in WT-animals. The leukotrienes synthesis
inhibition and the receptor blockade in bleomycin treated
mice significantly reduced the fluid content (Fig. 1f) and
the neutrophil infiltration (Figs. 2d) as evaluated by MPO
activity assay. Neutrophil activity was also evaluated
immunohistochemically by MPO staining of lung sec-
tions, demonstrating a strong alveolar neutrophils infil-
tration (Fig. 2a). This effect was completely abrogated in
MK-571 and Zileuton treated animals (Figs. 2b,c).
Immunohistochemical analysis revealed a positive stain-
ing for IL-1β mostly in inflammatory cell infiltrate present
in the interstitium and in the airspace (i.e. alveolar macro-
phages) but also in the vascular zone (i.e. vascular
endothelium) in bleomycin-group (Fig. 3a). In contrast,
no staining for IL-1β was found in the lungs of MK-571
(Fig. 3b) and Zileuton groups (Fig. 3c).Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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Effect of leukotrienes pathway pharmacological inhibitionon lung injury Figure 1
Effect of leukotrienes pathway pharmacological inhibitionon lung injury. Van Gieson stain: × 150. The used stain 
shows collagen in purple. A: Bleomycin alone in WT mice. B: Magnified lung section of Bleomycin alone in WT mice, × 300. C: 
Bleomycin in MK-571 treated mice. D: Bleomycin in Zileuton treated mice. All showed sections come from the left middle 
lobe. Each image is representative of at least 3 experiments. E: Lung fibrosis as evaluated by Ashcroft criteria[17]. F: Effect of 
pharmacological leukotrienes activity inhibition on edema in the lung. Black bar represents control group, grey bar MK-571 
group and white bar Zileuton group. Data are means ± SEM from 15 mice for each group. *p < 0.01 versus sham. °p < 0.01 vs. 
bleomycin.Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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Similarly, a substantial increase in the lung TNF-α stain-
ing of bronchial epithelial cells was evident in bleomycin
group (Fig. 3e). This effect was reduced in lung sections of
MK-571 (Fig. 3f) and Zileuton treated animals (Fig. 3g)
caused by bleomycin intratracheal administration. There
was no IL-1β or TNF-α staining in lung sections of sham-
operated animals.
The severe lung injury caused by bleomycin administra-
tion was associated with a significant loss in body weight
Effect of pharmacological leukotrienes activity inhibition on lung myeloperoxidase Figure 2
Effect of pharmacological leukotrienes activity inhibition on lung myeloperoxidase. Immunohistochemical localiza-
tion of myeloperoxidase in the lung. A: Bleomycin alone in WT mice. B: Bleomycin in MK-571 treated mice. C: Bleomycin in 
Zileuton treated mice. Original magnification: 150×. Each image is representative of at least 3 experiments. D: Effect of pharma-
cological leukotrienes activity inhibition on lung myeloperoxidase activity. Black bar represents control group, grey bar MK-571 
group and white bar Zileuton group. Data are means ± SEM from 15 mice for each group. *p < 0.01 versus sham. °p < 0.01 vs. 
bleomycin.Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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Effect of pharmacological leukotrienes activity inhibition on lung IL-1 and TNF-α immunostaining Figure 3
Effect of pharmacological leukotrienes activity inhibition on lung IL-1 and TNF-α immunostaining. After bleomy-
cin injection in WT mice, positive staining for IL-1 (A) was localized mainly in inflammatory cells and in vascular endothelium. 
There was a marked reduction in the IL-1 immunostaining in the lungs of MK-571 group (B) and in the lungs of Zileuton group 
(C). TNF-α was localized mainly in inflammatory cells and in bronchial epithelium of lungs in the bleomycin group (E). A 
marked reduction in TNF-α immunostaining in lungs of MK-571 (F) and in Zileuton group (G). Original magnification: 150×. 
This figure is representative of at least 3 experiments performed on different experimental days.Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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and survival (Figs. 4a,b). Leukotrienes synthesis blockade
and the receptor antagonism in bleomycin treated mice
significantly attenuated the loss in body weight. Bleomy-
cin-treated WT mice developed severe lung injury and
33% of these animals died within one week after bleomy-
cin administration. None of the MK-571 or Zileuton
treated animals died after bleomycin instillation within
the one week period of study.
BAL total cellularity significantly increased in bleomycin
exposed animals (Fig. 5a). MK-571 and Zileuton groups
showed a reduction in BAL cellularity when compared to
bleomycin group.
Differential cell counts showed a similar profile across all
of the sham groups. In the bleomycin group there was a
significant increase of macrophages, lymphocytes and
neutrophils compared to sham group.
MK-571 and Zileuton treated mice showed a decreased
content of BAL inflammatory cells as evaluated on cyt-
ospins preparations (Fig. 5b). In these mice macrophages,
lymphocytes and neutrophils were significantly reduced
compared to bleomycin group.
Discussion
Common pathologic features in interstitial lung diseases
include the fibrosis of the interstitium, involve collagen,
elastic and smooth muscle elements, architectural remod-
elling and chronic inflammation[18].
Lipid mediators are thought to be involved in lung fibro-
sis. Cysteinyl leukotrienes as well as LT-B4 are elevated in
lung homogenates and bronchoalveolar lavage of patients
with IPF [19-21]. In lung fibroblasts, leukotrienes stimu-
late collagen synthesis, chemotaxis, and transformation
into myofibroblasts [22-24].
Observations on the role of leukotrienes in vivo come
from the experimental model of bleomycin-induced lung
fibrosis. Intratracheal instillation of the antitumour agent
bleomycin is the most commonly used animal model for
pulmonary fibrosis[25]. Earlier reports point out that the
pathogenesis of bleomycin-induced fibrosis, at least in
part, is mediated through the generation of reactive oxy-
gen species which cause the peroxidation of membrane
lipids and DNA damage[26].
Early attempts to target the arachidonic acid metabolism
in this experimental model were performed using a phar-
macological approach. Lpoxygenase inhibitor nordihy-
droguaiaretic acid was proved to attenuate bleomycin-
induced lung fibrosis and to reduce both the macrophage
infiltrate and the fibroblast growth factor release after ble-
omycin administration[27]. However, this compound is
characterized by a non-specific action on arachidonic acid
metabolism and has proved to possess a direct anti-oxi-
dant activity [28]. Similarly, gamma-linolenic acid was
able to suppress LT-B4 synthesis and lung damage in this
model[29], but again its action is not limited to the ara-
chidonic acid pathway[30].
Recently, leukotrienes pathway in this model has been
dissected by genetically targeting the different enzymes
responsible for the synthesis of eicosanoids. Indeed, lung
fibrosis and inflammation were attenuated by the disrup-
tion of the gene encoding phospholipase A2  in this
model[31]. Peters-Golden et al[32], demonstrated how 5-
LO deficient mice were protected by bleomycin-induced
lung fibrosis, thus confirming LT role in experimental pul-
monary fibrosis. More recently, Beller and colleagues have
demonstrated a role for LT-C4 synthase and for the cystei-
nyl leukotriene receptors in the pathogenesis of the
fibrotic lung damage following bleomycin. Whereas the
cys-LT1 receptor is involved in the acute damage, cys-LT2
receptor is thought to be responsible for the chronic injury
following bleomycin administration[33,34].
However, it has to be underscored that murine alveolar
macrophages present higher levels of cys-LTs than LTB4
with an inverted ratio between the two [35]. Thus, murine
models are expected to exaggerate the importance of cys-
LTs relative to what would occur in humans [36].
Considering that overproduction of 5-LO products occurs
in the bleomycin animal model of lung fibrosis, and that
previous studies on genetic knock out of different
enzymes involved in leukotrienes synthesis have shown a
significant protection from bleomycin induced fibrosis,
we sought to assess the role of drugs that target the leuko-
triene pathway either at the synthetic step or at the recep-
tor level.
In the current study, we used MK-571 as a specific cys-LT1
receptor antagonist[37]. This compound has similar bio-
chemical and pharmacological properties to other anti-
leukotrienes drugs such as montelukast, currently used to
treat bronchial asthma and allergic rhinitis. Whereas
Zileuton is a reversible 5-LO inhibitor approved for the
treatment of asthma in humans. It is noteworthy that
zileuton dose used in our experimental setup was very
close to that clinically used in humans (1.5 times). On the
other hand, it is not possible to estimate a relative dose for
MK571, because of the unavailability of human studies
with this particular compound.
Here we show a significant reduction of tissue damage in
lungs of bleomycin-treated mice which received the treat-
ment with both MK-571 or Zileuton. Not only did the
matrix deposition evaluated histologically in lung sec-Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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Effect of pharmacological inhibition of leukotrienes activity on body weight (A) and survival (B) Figure 4
Effect of pharmacological inhibition of leukotrienes activity on body weight (A) and survival (B).  represents 
bleomycin group, ● MK-571 treated animals and Δ Zileuton treated animals. Data are means ± SEM from 15 mice for each 
group. *p < 0.01 vs. bleomycin.Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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Effect of pharmacological inhibition of leukotrienes on bleomycin-induced total (A) and differential cellularity (B) ofbronchoal- veolar lavage (BAL) Figure 5
Effect of pharmacological inhibition of leukotrienes on bleomycin-induced total (A) and differential cellularity 
(B) ofbronchoalveolar lavage (BAL). Total and differential cells counts for macrophages, lymphocytes, neutrophils and 
eosinophils per mL of BAL fluid are shown. Data, expressed as means ± SEM, are representative of 15 mice for each group. ° p 
< 0.001 vs. sham, *p < 0.05 vs. bleomycin.Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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tions of treated mice show a reduced degree of fibrosis,
but also the alveolar architecture was preserved, indicating
that the treatment with leukotrienes antagonists effec-
tively prevented the bleomycin lung damage. In animals
treated with MK-571 or Zileuton, lung edema and fall of
body weight were virtually absent and inflammatory cells
in BAL were significantly reduced. Moreover, we observed
a significant reduction of leukocyte infiltration as assessed
by the specific granulocyte enzyme MPO. Consistent with
proinflammatory cell infiltrate and MPO activity we
found that TNF-α was upregulated following intratracheal
bleomycin administration. The TNF-α increase was com-
pletely abrogated in mice treated with MK-571 and Zileu-
ton.
TNF-α is an "early-wave" cytokine, its role is recognized in
a number of fibrotic human pulmonary pathologies[38].
It can induce apoptosis of respiratory epithelium which
contributes to the alveolar damage in IPF. Moreover, there
is evidence that TNF-α can upregulate the expression of
the well known profibrotic cytokine TGF-β1 [39]. In fact,
TNF-α blockade with either anti-TNF-α antibodies or
TNF-α antagonists can inhibit fibrosis[40]. A cys-LT recep-
tor 1 antagonist has been proved able to reduce the NF-kB
activation and thus cytokines synthesis in vitro, and in par-
ticular TNF-α may be reduced secondarily to this
effect[41]. The mechanisms of TNF-α pro-inflammatory
activity are likely to involve both direct effects of TNF-α
itself on regulation of adhesion molecule expression and
induction of other cytokines and growth factors capable
of mediating leukocyte chemotaxis and survival. Thus, it
is conceivable that leukotrienes blockade results in a
reduced inflammatory infiltrate in the lung following ble-
omycin administration and in an indirect effect on the
active TGF-β levels in this model.
Similarly to TNF-α, we show that interleukin-1 (IL-1) is
upregulated following bleomycin administration.
Interleukin-1β is one of the major extracellular proinflam-
matory cytokines, it is involved fibrotic process and is
known to act synergistically with TNF-α [42].
Inhibition of IL-1β prevented the fibrotic reaction
induced by bleomycin in mice[43], while its transient
expression induces lung injury and pulmonary fibrosis in
the late stages of the experimental setting [44].
We show that the IL-1β increase was almost abrogated in
mice treated with MK-571 and Zileuton. This class of
pharmacological agents has already shown the ability to
suppress IL-1 secretion in cultured synovial tissue explants
[45], potentially affecting the inflammatory cells infiltrate
in tissues and thus the fibrotic response determined by the
cascade of cytokines secreted following increased IL-1β
release.
Finally, the beneficial effects given by the leukotrienes
pharmacological blockade resulted in the abrogation of
the mortality at 7 days after bleomycin.
To determine whether LTs play a causal role in fibrotic
lung disease, we choose an interventional strategy to tar-
get both cysteinyl-LTs as well as LTB4 in the case of Zileu-
ton or only cysteinyl-leukotrienes in the case of MK-571.
This approach was selected on the basis of evidence that
both classes of LTs are elevated in the bleomycin model as
well as in human IPF [46]. Both classes of LTs have impor-
tant actions that are fully relevant to inflammation as well
as fibrogenesis.
Our data shows that both treatments granted a very simi-
lar degree of protection from bleomycin, with no evident
differences between the two drugs in any of the parame-
ters investigated. This might suggest on a first basis that
leukotriene B4 have not a predominant role in mediating
inflammation and fibrosis at least in bleomycin treated
mice.
It has previously been demonstrated in a mouse model
that cys-LT2  receptor is responsible for the fibrotic
response to bleomycin administration by using a genetic
approach to target this leukotrienes receptor [47]. We
found that MK-571, a pharmacological cys-LT1 receptor
antagonist, is able to block such response as well. Experi-
mental gene disruption technique might generate a dis-
crete number of variables that makes not feasible a
straight parallel with a pharmacological study. On the
other hand the receptor specificity of a pharmacological
compound such as MK-571 is influenced by several fac-
tors related with pharmacological properties of the com-
pound itself. In fact, although MK-571 is a specific cys-LT1
receptor antagonist, it possesses additional effects on leu-
kotrienes methabolism. Indeed, this compound has been
shown to inhibit the ubiquitously expressed multidrug
resistance protein 1 (MRP1) as well [48]. MRP1 belongs to
the ATP binding cassette transporter superfamily [49], its
major physiological role is thought to be ATP-dependent
transporter of LT-C4.
MRP1 knock out mice show a reduced inflammatory
response induced by arachidonic acid due to impaired LT-
C4 secretion [50]. Similarly, the specific MRP1 inhibitor
MK571 is able to suppress LT-C4 transport in vitro [51].
MRP1 role in immunological responses is not limited to
eicosanoids secretion. In example, MRP1 is implicated in
T helper responses. MRP1 is constitutively expressed on
Th2 cells while antigen or cytokine stimulation upregu-Respiratory Research 2006, 7:137 http://respiratory-research.com/content/7/1/137
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lates its expression on Th1 cells. MK571 has proved to
depress T helper responses by decreasing the release of
several cytokines such as IL-4, IFN-γ and TNF-α [52].
Considering this, it is tempting to speculate that the pro-
tective and anti-inflammatory effect of MK571 we
observed could be linked to cys-LT1 receptor blockade as
well as impaired cys-LT transport through MRP1. Further
research is needed to address the relative role of the dual
mechanism of action of MK571 in the bleomycin model
of injury. The interest in MK571 action on LT-C4 transport
is relatively recent. Nevertheless, a vast number of studies
currently employ this compound as a cys-LT1 receptor
antagonist both in vitro and in vivo.
In summary, we have provided the first evidence that anti-
leukotrienes, drugs commonly used for their anti-inflam-
matory properties to treat asthma and allergic rhinitis, are
able in the bleomycin animal model of lung fibrosis to
attenuate the acute lung injury and the evolution of
fibrotic lung lesions associated with the administration of
this anticancer agent.
The beneficial activity of this pharmacological interven-
tion was reflected on some favourable clinical outcomes
such as reduced body weight loss, tissue edema and most
notably mortality rate. Taken together, our data might fur-
ther support the rationale for a clinical trial in interstial
lung diseases as well as in other fibrotic diseases of the
lung interstium including those associated with the usage
of known causative drugs using antileukotriene com-
pounds currently available for human use.
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